U.K. allergy drug reclassification
This article was originally published in The Tan Sheet
Executive Summary
Galpharm Healthcare requests the Medicines and Healthcare products Regulatory Agency expand the pack size limit of its Galpharm Non-Drowsy Hayfever and Allergy Relief Tablets (loratadine 10 mg tablets) for general sale. The drug currently has general sale status in the U.K. with a maximum pack size of seven tablets, and the firm requests that the agency increase the allowable pack size for general sale to 14 tablets. MHRA published the request on its Web site Aug. 27 and requests comments on the issue by Sept. 25. The drug has been available in the seven-tablet pack for general sale since 2003, and larger packs have been available in pharmacy only sales since 1993
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.